---
input_text: 'Thalidomide as treatment of crohn-like disease occurred after allogeneic
  hematopoietic stem cell transplantation in a pediatric patient. BACKGROUND: Autoimmune
  diseases may occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  and inflammatory bowel disease (IBD or Crohn disease) is rarely described. We describe
  a child who developed CD after allo-HSCT, successfully treated with thalidomide.
  CASE REPORT: A child affected by mucopolysaccharidosis type I received two allogeneic
  HSCTs for rejection after the first one. After cutaneous and intestinal chronic
  GvHD and 6 months after HSCT, the patients developed a trilinear autoimmune cytopenia
  successfully treated with rituximab and sirolimus. Due to persisting intestinal
  symptoms, colonoscopies were performed and histological findings demonstrated a
  picture of CD. Based on this observation and according to the recommendations for
  the treatment of CD, thalidomide was started. A complete stable clinical response
  was obtained 8 weeks after start of thalidomide. Colonoscopy performed 4.8 years
  later demonstrated a complete endoscopic and histological remission of CD. DISCUSSION:
  In this case, the diagnosis of CD after HSCT was based on histological findings.
  Indeed, repeated colonscopies were necessary for diagnosis, since both clinical
  and endoscopic features are often common to chronic GvHD and CD. Thalidomide was
  started at the dose of 1.7 mg/Kg/day, and it was well tolerated. Mild peripheral
  neurotoxicity occurred 5 years later but disappeared completely with the dose reduction.
  Currently, the patient is in complete remission from CD, despite the discontinuation
  of all the immunosuppressive therapies. CONCLUSIONS: Thalidomide could represent
  a therapeutic option to treat CD as autoimmune disease after allogeneic HSCT.'
raw_completion_output: |-
  primary_disease: Crohn disease (CD)

  medical_actions: Hematopoietic stem cell transplantation (HSCT); colonoscopies; thalidomide administration; rituximab administration; sirolimus administration; dose reduction

  symptoms: mucopolysaccharidosis type I; cutaneous and intestinal chronic GvHD; trilinear autoimmune cytopenia; intestinal symptoms

  chemicals: thalidomide; rituximab; sirolimus

  action_annotation_relationships: Hematopoietic stem cell transplantation (HSCT) TREATS mucopolysaccharidosis type I IN Crohn disease; rituximab (with sirolimus) TREATS trilinear autoimmune cytopenia IN Crohn disease; thalidomide TREATS intestinal symptoms IN Crohn disease; dose reduction PREVENTS peripheral neurotoxicity IN Crohn disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  dose reduction PREVENTS peripheral neurotoxicity IN Crohn disease

  ===

extracted_object:
  primary_disease: MONDO:0016063
  medical_actions:
    - MAXO:0000747
    - MAXO:0001184
    - thalidomide administration
    - rituximab administration
    - sirolimus administration
    - dose reduction
  symptoms:
    - mucopolysaccharidosis type I
    - cutaneous and intestinal chronic GvHD
    - trilinear autoimmune cytopenia
    - intestinal symptoms
  chemicals:
    - CHEBI:9513
    - CHEBI:64357
    - CHEBI:9168
  action_annotation_relationships:
    - subject: MAXO:0000747
      predicate: TREATS
      object: mucopolysaccharidosis type I
      qualifier: MONDO:0005011
    - predicate: TREATS
      object: trilinear autoimmune cytopenia
      qualifier: MONDO:0005011
      subject_extension: CHEBI:64357
    - subject: thalidomide
      predicate: TREATS
      object: intestinal symptoms
      qualifier: MONDO:0005011
    - subject: <dose reduction>
      predicate: <PREVENTS>
      object: <peripheral neurotoxicity>
      qualifier: <Crohn disease>
      subject_extension: <dose reduction>
named_entities:
  - id: MONDO:0001586
    label: mucopolysaccharidosis type I
  - id: MONDO:1012617
    label: Mucopolysaccharidosis Type I (MPS I)
  - id: CHEBI:60285
    label: DOPE
  - id: MAXO:0001521
    label: nasal administration
  - id: MONDO:0011758
    label: Mucopolysaccharidosis type I Hurler (MPSIH)
  - id: MAXO:0000747
    label: hematopoietic stem cell transplantation (HSCT)
  - id: MAXO:0000487
    label: clinical assessment (growth measurement, kyphosis and genu velgum evaluation)
  - id: HP:0002808
    label: kyphosis
  - id: HP:0001376
    label: limited joint mobility
  - id: HP:0008807
    label: acetabular dysplasia
  - id: MAXO:0010034
    label: Corneal transplantation
  - id: HP:0007957
    label: Corneal clouding
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: HP:0000238
    label: Hydrocephalus
  - id: MAXO:0000068
    label: transplantation
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000526
    label: clinical examination
  - id: CHEBI:143889
    label: glycosaminoglycan (GAG)
  - id: HP:0004322
    label: short stature
  - id: HP:0005619
    label: thoracolumbar kyphosis
  - id: HP:0000943
    label: dysostosis multiplex
  - id: MONDO:0011759
    label: Hurler-Scheie syndrome
  - id: HP:0001387
    label: joint stiffness
  - id: HP:0000403
    label: recurrent otitis media
  - id: HP:0001999
    label: facial dysmorphism
  - id: HP:0002781
    label: Upper airway obstruction
  - id: HP:0001638
    label: Cardiomyopathy
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:58187
    label: Alginate
  - id: CHEBI:53412
    label: PLL (Poly-L-lysine)
  - id: CHEBI:50594
    label: Carbon nanotubes
  - id: HP:0007663
    label: Reduced visual acuity
  - id: MAXO:0000016
    label: cellular therapy
  - id: CHEBI:19226
    label: Tm
  - id: MONDO:0017385
    label: mucopolysaccharidosis type I (MPSI) Hurler
  - id: MAXO:0000018
    label: Biomarker assessment
  - id: HP:0001138
    label: Optic neuropathy
  - id: HP:0000488
    label: Retinopathy
  - id: MONDO:0019052
    label: Inborn errors of metabolism
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:33310
    label: MCT (NE)
  - id: HP:0001367
    label: joint disease
  - id: HP:0002652
    label: skeletal dysplasia
  - id: HP:0000618
    label: vision impairments
  - id: HP:0000365
    label: hearing impairments
  - id: MONDO:0007147
    label: Obstructive sleep apnea syndrome (OSAS)
  - id: MAXO:0000915
    label: Overnight polysomnography (PSG)
  - id: HP:0002104
    label: Apnea
  - id: HP:0040213
    label: Hypopnea
  - id: MAXO:0010033
    label: Umbilical cord blood transplantation
  - id: MONDO:0009290
    label: Pompe Disease
  - id: HP:0005162
    label: Left ventricular failure
  - id: HP:0011675
    label: Conduction abnormalities
  - id: HP:0001677
    label: Coronary artery disease
  - id: HP:0001433
    label: Hepatosplenomegaly
  - id: HP:0033126
    label: Necrosis
  - id: CHEBI:46793
    label: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(amino[polyethylene glycol]-
      2000) (DSPE-PEG)
  - id: CHEBI:17754
    label: Glycerol
  - id: CHEBI:15377
    label: Water
  - id: CHEBI:27881
    label: Resveratrol
  - id: HP:0010864
    label: severe mental retardation
  - id: CHEBI:82467
    label: Evans blue
  - id: MONDO:0006249
    label: mucopolysaccharidoses (MPS)
  - id: CHEBI:232920
    label: Alginate-poly-L-lysine-alginate (APA)
  - id: HP:0000708
    label: Behavioral abnormalities
  - id: HP:0033429
    label: Neuroinflammation
  - id: MAXO:0001525
    label: Intravenous administration
  - id: HP:6000847
    label: cardiac mass
  - id: HP:0012393
    label: Allergic reactions
  - id: HP:0001268
    label: Cognitive decline
  - id: HP:0000388
    label: Otitis media
  - id: HP:0000750
    label: Language delays
  - id: MAXO:0000479
    label: Orthopedic surgeries
  - id: HP:0011947
    label: Respiratory infections
  - id: CHEBI:28088
    label: Genistein
  - id: MAXO:0000506
    label: Non-invasive ventilation
  - id: HP:0002091
    label: Restrictive lung disease
  - id: HP:0001513
    label: Obesity
  - id: HP:0000822
    label: High blood pressure
  - id: HP:0001626
    label: Cardiovascular abnormalities
  - id: CHEBI:18376
    label: dermatan sulfate
  - id: CHEBI:28815
    label: heparan sulfate
  - id: CHEBI:37397
    label: chondroitin sulfate
  - id: CHEBI:15971
    label: heparan sulfate (HS)
  - id: CHEBI:17053
    label: dermatan sulfate (DS)
  - id: CHEBI:16991
    label: DNA
  - id: HP:0001385
    label: Hip dysplasia
  - id: HP:0001263
    label: Cognitive delay
  - id: CHEBI:50693
    label: Milrinone
  - id: MAXO:0000011
    label: Physical therapy
  - id: HP:0003423
    label: Thoracolumbar kyphoscoliosis
  - id: HP:0002970
    label: Genua vara
  - id: HP:0002650
    label: Scoliosis
  - id: HP:0002857
    label: Genua valga
  - id: HP:0003311
    label: Odontoid hypoplasia
  - id: HP:0100543
    label: cognitive impairment
  - id: HP:0002180
    label: neurodegeneration
  - id: CHEBI:50803
    label: nanoparticles
  - id: HP:0002176
    label: spinal cord compression
  - id: HP:0012531
    label: pain (injection site, back, groin)
  - id: HP:0002315
    label: headache
  - id: HP:0033482
    label: limited shoulder flexion
  - id: HP:0004349
    label: decreased bone mineral density
  - id: HP:0000924
    label: skeletal anomalies
  - id: HP:0002240
    label: hepatomegaly
  - id: HP:0010619
    label: correlation of reaction time with fractional anisotropy (FA) in frontal
      and parietal white matter
  - id: HP:0003541
    label: Urinary glycosaminoglycan (GAG) excretion
  - id: HP:0002870
    label: Obstructive sleep apnea syndrome (OSAS)
  - id: HP:0001653
    label: mitral regurgitation
  - id: HP:0001712
    label: LVH (left ventricular hypertrophy)
  - id: HP:0001655
    label: PFO (patent foramen ovale)
  - id: HP:0001250
    label: seizure
  - id: HP:0000505
    label: Visual impairment
  - id: HP:0000481
    label: corneal abnormalities
  - id: HP:0000716
    label: depression
  - id: HP:0000752
    label: hyperactivity
  - id: HP:0007018
    label: attention deficit disorder
  - id: HP:0010535
    label: Sleep apnoea
  - id: CHEBI:4439
    label: Dermatan
  - id: MONDO:0002561
    label: Lysosomal Storage Disorders (LSDs)
  - id: CHEBI:36080
    label: protein
  - id: MONDO:0016063
    label: Crohn disease (CD)
  - id: MAXO:0001184
    label: colonoscopies
  - id: CHEBI:9513
    label: thalidomide
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:9168
    label: sirolimus
  - id: MONDO:0005011
    label: Crohn disease
